TiumBio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
TiumBio is a South Korean biotech company, listed on KOSDAQ, that researches and develops treatments for rare and hard-to-treat diseases.
It works across two drug-discovery approaches, small-molecule synthetic drugs and biologic drugs, selecting whichever method best suits the disease target. The company's pipeline is aimed at patients and healthcare systems that need therapies for conditions with limited existing options.
Summary is AI-generated and may contain errors · figures from DART filings
TiumBio was founded by the chief executive and core researchers who previously developed the hemophilia biologic Afstyla at SK Chemicals and completed a technology-licensing deal for it.
TiumBio in five facts
What does TiumBio do?
TiumBio is a South Korean biotech company, listed on KOSDAQ, that researches and develops treatments for rare and hard-to-treat diseases.
Where is TiumBio listed and in which sector?
TiumBio (Korean name: 티움바이오) trades under KRX code 321550 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is TiumBio?
Its market capitalisation was US$95.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were TiumBio's latest annual revenue and operating profit?
For fiscal year 2025, TiumBio reported revenue of US$9.3M, an operating loss of US$12.2M and a net loss of US$14.2M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 80.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureSep 30
- Grant of stock optionsSep 30
- [Amended] Grant of stock optionsSep 30
- [Amended] Grant of stock optionsSep 30
- [Amended] Grant of stock optionsSep 30
- [Amended] Grant of stock optionsSep 30
- Conversion price adjustmentSep 23
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
TiumBio reported consolidated results for FY2025: revenue of US$8.44M (+80.92% year on year), an operating loss of US$11.1M and a net loss of US$13.3M.
Earnings · Feb 11